Skip to content

Intelligent Development and Real-World Validation of a Hybrid AI System for Pretest Probability Assessment of Coronary Artery Disease

Intelligent Development and Real-World Validation of a Hybrid AI System for Pretest Probability Assessment of Coronary Artery Disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107332
Enrollment
Unknown
Registered
2025-08-08
Start date
2025-08-08
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ??1.Patients with suspected coronary artery disease (CAD) presenting with chest pain or other thoracic discomfort; ??2.Aged 18 to 75 years;?? ??3.Patients and their legal representatives comprehend and cooperate with the intervention strategy of the collaborative framework for PTP assessment of patients with suspected CAD, and provide written informed consent.?

Exclusion criteria

Exclusion criteria: ??1. History of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), occluder implantation, prosthetic valve replacement, or permanent pacemaker implantation; ??2. Heart failure patients with New York Heart Association (NYHA) functional class III-IV;?? ??3. Prior history of myocardial infarction or myocarditis;? ??4. Hemodynamic or clinical instability, including systolic blood pressure <90 mmHg, severe arrhythmias, valvulopathy, cardiomyopathy, or intracardiac thrombus;?? ??5. Refusal or inability to provide informed consent by patients or legal representatives;?? ??6. Life expectancy <12 months due to significant non-cardiac comorbidities;?? ??7. Congenital heart disease or inherited cardiac disorders;?? ??8. Planned use of pacemakers or vasodilating agents;?? ??9. Concurrent participation in another interventional clinical trial with unevaluated primary endpoints.?

Design outcomes

Primary

MeasureTime frame
Diagnostic Performance;Information Extraction Efficacy;Operation Efficiency;

Secondary

MeasureTime frame
Clinical Utility;Model Robustness;Human-AI Synergy Quality;

Countries

China

Contacts

Public ContactYundai Chen

Chinese PLA General Hospital

cyundai@vip.163.com+86 133 1111 9778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026